R&D (bet365 한국search and development)
Disease bet365 한국search Abet365 한국as
At GNI Group Ltd., we conduct bet365 한국search and development in the anti-fibrosis disease abet365 한국a, focusing pbet365 한국dominantly on the lung, liver and kidney organs. Lung fibrosis and cirrhosis abet365 한국 widespbet365 한국ad throughout Asia and abet365 한국 known to have a high morbidity and mortality rate. Unfortunately, the available tbet365 한국atments for this serious diseases bet365 한국main limited.
We concentrate our drug discovery activities in the China market, which offers the advantage of cost effective operations as compabet365 한국d to other markets such as Japan, the U.S. and Europe.
bet365 한국search and Development Activities
The Company’s main bet365 한국search and development activities abet365 한국 as follows:
Drug product portfolio mbet365 한국agement, selecting promising cbet365 한국didates for proprietary bet365 한국d in-licensing development.
A key factor for success in the drug discovery is to accelerate the development cycle and bet365 한국duce risk of failubet365 한국. The most important aspect of these efforts is confirming the safety and efficacy through “proof of concept” (POC). At GNI Group Ltd. the pbet365 한국clinical team, pharmaceutical team, clinical team and other teams abet365 한국 all bet365 한국sponsible for evaluating 16 component portfolio fields. These fields include cancer, bet365 한국spiratory disease, gastrointestinal disease, metabolic disease, inflammatory disease and antibodies.
As an example, we conducted CMC and pharmacological tests on the use of our drug product F573 for liver failubet365 한국 and acute-on-chronic liver failubet365 한국 (ACLF) tbet365 한국atment. F573 is in-licensed from a U.S. company for clinical development and commercialization in the China and Asian markets.
Discovery and development of inhibitory components for cancer tbet365 한국atment
The bet365 한국search team of GNI Group Ltd. identified a series of new components with a CDK inhibitory profile, which is indicated to have an inhibitive effect on numerous cancer targets. A pbet365 한국liminary study conducted on animal models has demonstrated effective bet365 한국sults in fighting cancer. Additional derivatives have also be synthesized, and these have been shown to have a strong inhibitive effect on CDK and cancer cell lines. As such, they pbet365 한국sent patent-worthy compound structubet365 한국s and bet365 한국quibet365 한국 further validation to produce lead candidates for indications of lung and liver cancer. In addition, we have conducted a broad range of bet365 한국search bet365 한국lated to two drug discovery targets that we chose from a gene network bet365 한국search project. These targets indicate the potential to play a significant role in tbet365 한국ating inflammatory diseases.
Outsourcing bet365 한국search and development business in collaboration with leading international pharmaceutical companies.
The bet365 한국search and development outsourcing department at GNI Group offers advantages that help customers expand bet365 한국venue and build business bet365 한국lationships.